Secondary acute myelocytic leukemia after successful chemotherapy with etoposide for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Kitazawa
J
J
Department of Pediatrics, Hirosaki University, School of Medicine, Aomori 036-8563, Japan.
Ito
E
E
Arai
K
K
Yokoyama
M
M
Fukayama
M
M
Imashuku
S
S
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use; D002675:Child, Preschool; D016572:Cyclosporine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000188:drug therapy*; D005047:Etoposide / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D015616:Histiocytosis, Non-Langerhans-Cell / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced*; D016609:Neoplasms, Second Primary / Q000139:chemically induced*
D000972:Antineoplastic Agents, Phytogenic; D007166:Immunosuppressive Agents; D005047:Etoposide; D003907:Dexamethasone; D016572:Cyclosporine